First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - Paz-Ares, L; Ciuleanu, T; Cobo, M (Lancet Oncol, 2021)
et al.